Stoke Therapeutics plans to meet with the U.S. Food and Drug Administration (FDA) before the end of this year…
Articles by Margarida Maia, PhD
In a mouse model study of Dravet syndrome, males were seen to be more vulnerable to abnormal heartbeats and…
Stoke Therapeutics’ zorevunersen, a treatment that addresses the genetic cause of Dravet syndrome, continues to reduce the frequency…
Nine months of treatment with bexicaserin (LP352), an investigational oral small molecule from Longboard Pharmaceuticals, more than halved the…
Encoded Therapeutics has been cleared by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to begin clinical testing…
Health Canada has approved Epidiolex (cannabidiol) as an add-on treatment for seizures in adults and children, ages 2 and…
During clinical trials, side effects are more common in people who use cannabidiol (CBD) to treat some forms of epilepsy,…
Longboard Pharmaceuticals has finished enrolling patients in PACIFIC, its Phase 1b/2a clinical study of LP352, an investigational oral serotonin…
BMB-101, an oral serotonin agonist being developed by Bright Minds Biosciences for the treatment of Dravet syndrome and…
Up to 1 in 4 people with hard-to-treat epilepsy, including those with Dravet syndrome, were found to stop taking…